There was a significant decrease in VV plaque number in IL-4 + IL-13-treated KC cultures exposed to pyridone 6 and abrocitinib, and a dose-dependent reduction was also observed with ruxolitinib (Figure 3). This evidence concerns the gene IL13 and keratoconus.